Safety and efficacy of durvalumab (MEDI4736) in various solid tumors

Drug Design, Development and Therapy
Hui YangXuelei Ma

Abstract

The prominent immune checkpoint molecule, programmed cell death ligand-1 (PD-L1), is the object of increasing attention. Here, we report a meta-analysis investigating the safety and efficacy of durvalumab (MEDI4736), an inhibitor of PD-L1, in various solid tumors. A systematic search of PubMed, Embase, and related articles was performed. Safety data were analyzed using Comprehensive Meta-Analysis software program version 2. Ultimately, 17 studies with 1,529 patients were included in our analysis. The major adverse events associated with durvalumab were pruritus and fatigue, while pruritus, increased alanine transaminase, and increased aspartate aminotransferase were common among patients treated with a combination of durvalumab and tremelimumab. Higher PD-L1 expression was associated with a superior objective response rate. Durvalumab is safe in patients with many solid cancers and, in combination with tremelimumab, it has a tolerable safety profile and is associated with improved prognosis. PD-L1 expression is a biomarker of the efficacy of durvalumab.

Citations

Jul 6, 2019·Expert Opinion on Biological Therapy·Juliana Alvarez-Argote, Constantin A Dasanu
Nov 12, 2020·Pharmaceuticals·Nicola J NasserAbed Agbarya
Jan 19, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Danique GiesenMartin Pool
Nov 20, 2020·BMJ Case Reports·Shivangi GuptaDavid Prentice
Mar 2, 2021·Expert Opinion on Investigational Drugs·Alessandro RizzoGiovanni Brandi
Mar 12, 2021·Frontiers in Immunology·Mahdi Abdoli ShadbadBehzad Baradaran
Jul 4, 2020·Anti-cancer Agents in Medicinal Chemistry·Navgeet KaurRakesh K Sindhu
May 25, 2021·Nanomedicine·Jeaneen Venkatas, Moganavelli Singh
Jul 1, 2021·Immunotherapy·Nikolaos CharalampakisDimitrios Schizas
Nov 20, 2021·International Journal of Hematology·Grzegorz S NowakowskiJavier Munoz

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
biopsies
Assay

Clinical Trials Mentioned

NCT01693562
NCT02141347
NCT02143466
NCT02087423
NCT03334617

Software Mentioned

Comprehensive Meta - Analysis

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.